Related Experiment Video
Updated: May 17, 2026
11:20
Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology
Published on: March 21, 2018
KRAS mutation testing in metastatic colorectal cancer
1Cong Tan, Xiang Du, Department of Oncology, Shanghai Medical School, Fudan University, Shanghai 200032, China.
World Journal of Gastroenterology
|October 16, 2012
Summary
KRAS mutation testing is crucial for colorectal cancer treatment decisions, predicting response to anti-EGFR therapies. Standardized testing methods and combined analyses with other biomarkers are recommended for optimal patient management.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- KRAS mutations occur in 35-45% of colorectal cancers.
- KRAS codon 12/13 mutations predict poor response to anti-EGFR antibodies.
- KRAS mutational status is essential for colorectal cancer patient management.
Purpose of the Study:
- To review KRAS biology and advances in mutation testing.
- To discuss challenges in standardized KRAS testing.
- To explore combined biomarker analyses for colorectal cancer treatment.
Main Methods:
- Review of current KRAS mutation detection methods.
- Analysis of challenges in sample selection, processing, and testing.
- Discussion of complementary biomarker testing (BRAF, PIK3CA, PTEN, MSI).
Main Results:
- KRAS testing is a key tool for anti-EGFR therapy selection.
- Standardization of KRAS testing methods remains a challenge.
- Combined analysis of KRAS with other biomarkers (BRAF, PIK3CA, PTEN, MSI) is recommended.
Conclusions:
- Accurate KRAS mutational status determination is vital for personalized colorectal cancer therapy.
- Standardized testing protocols and integrated biomarker analysis are needed.
- Further research into optimal testing strategies and potential drawbacks is warranted.
Related Concept Videos
02:38The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...